CHMP Backs Baricitinib, Lifmior for Rheumatoid Arthritis

The EMA's CHMP recommended baricitinib for rheumatoid arthritis and Lifmior for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.
International Approvals

http://ift.tt/2hX1XKW